Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
about
Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centresDonepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions.Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care.Donepezil: a clinical review of current and emerging indications.ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): A Randomized Controlled Trial to Assess the Efficacy of Actovegin in Poststroke Cognitive Impairment.Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.Advances in the pharmacotherapy of Alzheimer's disease.Asking family about memory loss. Is it helpful?Improving clinical descriptions to understand the effects of dementia treatment: consensus recommendations.Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch.Predictors of sustained response to rivastigmine in patients with Alzheimer's disease: a retrospective analysis.Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease.Goal setting and attainment in Alzheimer's disease patients treated with donepezil.Pharmacologic treatment of adolescent and child schizophrenia.Clinical trials in mild cognitive impairment: lessons for the future.Caregiver-specific outcomes in antidementia clinical drug trials: a systematic review and meta-analysis.Alzheimer's disease: the benefits of early treatment.Improving drug trials for mild to moderate Alzheimer's disease.Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil.Synthesis and comparison of the meta-analyses evaluating the efficacy of memantine in moderate to severe stages of Alzheimer's disease.Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia.Can pharmacological treatment of behavioural disturbances in elderly patients with dementia lower the burden of their family caregiver?Measurement tools of resource use and quality of life in clinical trials for dementia or cognitive impairment interventions: protocol for a scoping review.Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease.Memantine in patients with moderate to severe Alzheimer's disease: meta-analyses using realistic definitions of response.Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease.Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items.Differences in drug therapy between dementia disorders in the Swedish dementia registry: a nationwide study of over 7,000 patients.Galantamine treatment in Alzheimer's disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6).Brief cognitive assessment of Alzheimer's disease in advanced stages: Proposal for a Brazilian version of the Short Battery for Severe Impairment (SIB-8).The use of everyday technology by people with dementia living alone: mapping out the difficulties.How can we get access to the experiences of people with dementia? Suggestions and reflections.Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.Do extrapyramidal features in Alzheimer patients treated with acetylcholinesterase inhibitors predict disease progression?Defining "early dementia" and monitoring intervention: what measures are useful in family caregiving?How to define treatment success using cholinesterase inhibitors.Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD.Examining the reliability of ADAS-Cog change scores.
P2860
Q28486268-C146635E-84BE-4C23-B218-A64EAC4E8C71Q30436664-3F76C7EF-B0BF-41F6-AF99-E022E8BA3CBDQ30443975-79DDE0E5-A7F1-475C-8416-649EA3D2483EQ33150809-EA61CB7C-9B58-4820-A24B-C600146DEB3BQ33601434-D18F662C-51B1-4E31-927A-C96ACAB7DA9BQ33939971-C4D63B99-B8F7-4DFA-92B5-3BBB280E3226Q34011160-8087D49E-42E0-4CE6-A386-F08B5AC1F4F2Q34722587-71479EA1-1AA6-4A9A-8EB2-078EF148D2EBQ34982567-5BBFE7DF-2164-4493-90C7-506D6EC22168Q35158572-49E703FC-444D-42B6-A801-A7089E4ADC4BQ35252005-403FC1BB-3AE6-48E8-877B-0994F3774EB2Q35460043-70F67213-5499-44C1-BAFA-9871AAEF7EB6Q35470044-CCF72CD5-57F4-447F-9B17-02A52B96EAA5Q36107249-5C1AF08D-7F2B-464F-A54A-D89F81EB6E6FQ36142255-0947FD52-E3F0-4AB4-876D-A14CFE1166F7Q36150950-2785300F-A12C-4F9B-B07F-5135224271EBQ36249975-E69243CA-6237-487B-B02D-03008C6108C7Q36806662-676094DA-7A89-4E41-BF2A-ACAF35D0975CQ36932284-A6E2CCC3-4495-4AE9-87AA-1B6A72273368Q37004843-94D16640-AF5F-419C-ABA2-F10507A94619Q37316293-DBEA7C2B-8401-4927-BAF8-D4C4A44A993BQ37474101-975D1D61-2855-46E7-AD06-CDE7B44A208BQ37609664-78951D76-C65E-4F14-8940-F1DDBCA7D57FQ37816073-2A77F751-55A2-4B6F-9E27-8F12EAB08E7AQ38150922-93C32B07-0586-4F78-B7ED-57A0F47B0082Q42668931-A8C23E82-D062-426B-A724-4433D81D09C4Q43099284-5EE72C42-85BF-4DFF-9E40-FA2501984178Q43099287-6D8CD9E8-BCC9-48BA-826E-2E7FCC103A01Q44908766-A46DD4D7-350E-4585-830D-76C22F372DEAQ46727035-90F586AD-52FA-4A3A-A2EB-8BAC323ED2C4Q47103059-4B0BE5C2-F75A-4152-A114-94678F30AEDAQ48693293-415B2246-3601-42C4-820F-CF8C2710AD27Q50106979-080444AD-F19E-4A59-8D3C-315B7456CA54Q50860260-D373EDF4-8E3A-4872-B9D3-D873CB5A2510Q51901829-F683D0AF-99F8-4964-BA83-72DC79EA8CDCQ51950899-21D93A71-BF9B-4379-B7FD-B4D8CDADD445Q53248201-4A06912E-BC4A-47CD-B4C3-787683B84074Q53328060-C2B74DAB-FDEE-4762-9954-E4453CFF8193Q53484554-28D8D8A9-84F6-402A-9D6A-15A7263B9465
P2860
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
@ast
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
@en
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
@nl
type
label
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
@ast
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
@en
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
@nl
prefLabel
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
@ast
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
@en
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
@nl
P2093
P2860
P356
P1476
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
@en
P2093
Gauthier S
Orgogozo JM
Rockwood K
Schneider L
Wilkinson D
P2860
P304
P356
10.1002/GPS.496
P407
P577
2001-07-01T00:00:00Z